XenoPort Inc-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:XenoPort Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013633
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:26
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
XenoPort Inc (XenoPort) is a bio-pharmaceutical company which develops and commercializes internally discovered product candidates for the treatment of neurological disorders. It develops Transported Prodrugs through the modification of chemical structure of existing drugs in the market. The company’s lead product, Horizant, (gabapentin enacarbil) is commercialized in the US and Japan for the treatment of restless legs syndrome. The company’s product pipeline includes, XP21279, an oral product candidate that uses naturally-occurring, high-capacity nutrient transporters in the gastrointestinal tract to promote efficient absorption into the body; and XP23829 for the treatment for patients with moderate-to-severe chronic plaque-type psoriasis and relapsing multiple sclerosis. The company, in clinical trial partnership with the National Institute on Alcohol Abuse and Alcoholism (NIAAA), has initiated a clinical trial for evaluating Horizant as a treatment for patients with alcohol use disorder. Xenoport is headquartered in Santa Clara, California, the US.

XenoPort Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
XenoPort Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
XenoPort Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
XenoPort Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
XenoPort Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
XenoPort Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
XenoPort Inc, Pharmaceuticals & Healthcare, Deal Details 10
Licensing Agreements 10
Dr. Reddy’s Labs Enters into Licensing Agreement with XenoPort for XP23829 10
Reckitt Benckiser Pharma Enters Into Licensing Agreement With XenoPort For Arbaclofen Placarbil 12
Equity Offering 13
XenoPort Files Shelf Registration Statement for Public Offering of Shares For USD150 Million 13
XenoPort Completes Public Offering Of Shares For US$85.8 Million 14
XenoPort Completes Public Offering Of Common Stock For US$46 Million 15
Debt Offering 16
XenoPort Raises USD115 Million in Private Placement of 2.5% Notes Due 2022 16
Acquisition 18
Arbor Pharma Acquires Shares of XenoPort in a Tender Offer 18
XenoPort Inc – Key Competitors 20
XenoPort Inc – Key Employees 21
XenoPort Inc – Locations And Subsidiaries 22
Head Office 22
Recent Developments 23
Financial Announcements 23
May 05, 2016: XenoPort Reports First Quarter Financial Results 23
Feb 25, 2016: XenoPort Reports Fourth Quarter and Year-End 2015 Financial Results 24
Appendix 26
Methodology 26
About GlobalData 26
Contact Us 26
Disclaimer 26

List of Tables
XenoPort Inc, Pharmaceuticals & Healthcare, Key Facts, 2015 2
XenoPort Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
XenoPort Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
XenoPort Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
XenoPort Inc, Deals By Therapy Area, 2011 to YTD 2017 8
XenoPort Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Dr. Reddy's Labs Enters into Licensing Agreement with XenoPort for XP23829 10
Reckitt Benckiser Pharma Enters Into Licensing Agreement With XenoPort For Arbaclofen Placarbil 12
XenoPort Files Shelf Registration Statement for Public Offering of Shares For USD150 Million 13
XenoPort Completes Public Offering Of Shares For US$85.8 Million 14
XenoPort Completes Public Offering Of Common Stock For US$46 Million 15
XenoPort Raises USD115 Million in Private Placement of 2.5% Notes Due 2022 16
Arbor Pharma Acquires Shares of XenoPort in a Tender Offer 18
XenoPort Inc, Key Competitors 20
XenoPort Inc, Key Employees 21

★海外企業調査レポート[XenoPort Inc-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Abzena Plc (ABZA):製薬・医療:M&Aディール及び事業提携情報
    Summary Abzena Plc (Abzena), formerly Polytherics Group Ltd, is a life science company that provides complementary services and technologies to enable the selection, development and manufacture of biopharmaceuticals products based on antibodies and other proteins. The company's technologies include …
  • Finning International Inc. (FTT):企業の財務・戦略的SWOT分析
    Finning International Inc. (FTT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Viacom, Inc.:企業の戦略・SWOT・財務情報
    Viacom, Inc. - Strategy, SWOT and Corporate Finance Report Summary Viacom, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Rubius Therapeutics Inc (RUBY):製薬・医療:M&Aディール及び事業提携情報
    Summary Rubius Therapeutics Inc (Rubius Therapeutics) is a biotechnology company that focuses on the development of medicines for the treatment of rare diseases, cancer and autoimmune diseases. The company through its rubius erythrocyte design (RED) platform engineer and culture Red Cell Therapeutic …
  • Allianz Group:企業の戦略・SWOT・財務情報
    Allianz Group - Strategy, SWOT and Corporate Finance Report Summary Allianz Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • KACO new energy GmbH:企業の戦略的SWOT分析
    KACO new energy GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • The Ultimate Software Group Inc (ULTI):企業の財務・戦略的SWOT分析
    The Ultimate Software Group Inc (ULTI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • Datalogic SpA (DAL):企業の財務・戦略的SWOT分析
    Datalogic SpA (DAL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Salvatore Ferragamo SpA (SFER):企業の財務・戦略的SWOT分析
    Salvatore Ferragamo SpA (SFER) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Amgen Inc (AMGN):企業の財務・戦略的SWOT分析
    Amgen Inc (AMGN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Institute of Organic Chemistry and Biochemistry AS CR vvi:製薬・医療:M&Aディール及び事業提携情報
    Summary Institute of Organic Chemistry and Biochemistry AS CR vvi (IOCB) is a research institute that offers organic chemistry and biochemistry for medical and environmental applications. The institute’s scientific research includes the fields of physico-organic chemistry and biochemistry, molecular …
  • PT AKR Corporindo Tbk (AKRA):企業の財務・戦略的SWOT分析
    Summary PT AKR Corporindo Tbk (AKR Corporindo), formerly PT Aneka Kimia Raya Tbk is a diversified company that distributes, trades, and markets basic chemicals, petroleum, and offers logistics and supply chain solutions. The company operates through its business divisions such as trading and distrib …
  • Northwest Biotherapeutics Inc (NWBO):製薬・医療:M&Aディール及び事業提携情報
    Summary Northwest Biotherapeutics Inc (NW Bio) is a development stage biotechnology company. It discovers and develops immunotherapy products to treat cancer. The company by utilizing its proprietary technology platform, DCVax, developed a robust pipeline of therapeutic product candidates. DCVax is …
  • Sky plc (SKY):企業の財務・戦略的SWOT分析
    Sky plc (SKY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • Lebara Group:企業の戦略的SWOT分析
    Lebara Group - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Astrazeneca Pharma India Ltd (ASTRAZEN):製薬・医療:M&Aディール及び事業提携情報
    Summary AstraZeneca Pharma India Ltd (AstraZeneca), a subsidiary of AstraZeneca Plc, is a biopharmaceutical company that discovers, develops, and commercializes medicines. The company offers products in the therapeutic areas of cardiovascular and metabolic diseases, respiratory, maternal healthcare, …
  • China Grand Pharmaceutical and Healthcare Holdings Ltd (512):企業の財務・戦略的SWOT分析
    Summary China Grand Pharmaceutical and Healthcare Holdings Ltd (China Grand) is an investment holding company that develops, manufacture and distributes pharmaceutical preparations, medical devices and pharmaceutical intermediates, specialized raw materials, and healthcare products. The company prov …
  • Tereos SA:企業の戦略的SWOT分析
    Tereos SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Th …
  • Freeport-McMoRan Inc:企業のM&A・事業提携・投資動向
    Freeport-McMoRan Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Freeport-McMoRan Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A …
  • AK Steel Holding Corp:企業の戦略・SWOT・財務情報
    AK Steel Holding Corp - Strategy, SWOT and Corporate Finance Report Summary AK Steel Holding Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆